Detalhe da pesquisa
1.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Lancet
; 401(10381): 1001-1010, 2023 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36848918
2.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Lancet
; 401(10381): 1011-1019, 2023 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36848919
3.
Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases.
J Pharmacol Exp Ther
; 388(3): 751-764, 2024 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673681
4.
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Ann Rheum Dis
; 2024 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569851
5.
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
Ann Rheum Dis
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423757
6.
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Ann Rheum Dis
; 83(1): 15-29, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827694
7.
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-stranded DNA monitoring.
Rheumatology (Oxford)
; 63(2): 525-533, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37208196
8.
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
J Rheumatol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38490668
9.
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
N Engl J Med
; 382(3): 211-221, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851795
10.
Macrophage migration inhibitory factor promotes glucocorticoid resistance of neutrophilic inflammation in a murine model of severe asthma.
Thorax
; 78(7): 661-673, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36344253
11.
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
Ann Rheum Dis
; 82(5): 639-645, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690388
12.
Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force.
Ann Rheum Dis
; 82(6): 788-798, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627168
13.
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
Rheumatology (Oxford)
; 62(4): 1526-1534, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36018235
14.
Patterns and prevalence of cognitive dysfunction in systemic lupus erythematosus.
J Int Neuropsychol Soc
; 29(5): 421-430, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37017062
15.
Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2'-O-methyl gapmer oligonucleotides.
Nucleic Acids Res
; 49(11): 6082-6099, 2021 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34057477
16.
Comparisons between US norm-based two-component and Japanese norm-based three-component SF-36 summary scores in systemic lupus erythematosus patients.
Mod Rheumatol
; 33(3): 517-524, 2023 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35689562
17.
The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
Mod Rheumatol
; 33(1): 134-144, 2023 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134970
18.
Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammation.
Immunol Cell Biol
; 100(8): 605-623, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35652357
19.
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Ann Rheum Dis
; 81(7): 962-969, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580976
20.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Ann Rheum Dis
; 81(7): 951-961, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35338035